MedPath

A Study of TAK-341 in Treatment of Multiple System Atrophy

Phase 2
Recruiting
Conditions
Multiple System Atrophy
Registration Number
JPRN-jRCT2011220029
Lead Sponsor
onomura Hidenori
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
138
Inclusion Criteria

Diagnostic:
1.The participant has a diagnosis of possible or probable MSA using the modified Gilman et al, 2008 diagnostic criteria.
2.The participant's onset of first MSA symptoms occurred =<4 years before screening, as assessed by the investigator.
3.Evidence of MSA specific symptoms and deficits as measured by the UMSARS scale.

Exclusion Criteria

Medical History:
1.The participant has any contraindication to study procedures.
Diagnostic Assessments:
1.Presence of confounding diagnosis and/or conditions that could affect participant's safety during the study per investigator judgement.
2.The participant's participation in a previous study of a disease-modifying therapy (with proven receipt of active treatment) will compromise the interpretability of the data from the present study, per consultation with medical monitor or designee.
Other:
1.The participant has participated in another study investigating active or passive immunization against alfa-synuclein (alfa-SYN) for progressive disease (PD) or MSA, or has had immunoglobulin G therapy, within 6 months before screening.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1.Change from Baseline in a Modified Unified Multiple System Atrophy Rating Scale (UMSARS) Part I at Week 52<br>Time Frame: Up to 52 weeks<br>UMSARS Part I (historical review) is a 11-item scale that was adapted from the Unified Parkinson's Disease Rating Scale (UPDRS) and is used to assess activities related to motor disability and related to autonomic dysfunction. Each item is scored from 1 (normal) to 4 (severe). The total score is a sum of scores from all domains and can range from 11 to 44. Higher scores mean poorer health.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath